Softr Unveils an AI-Native Platform, Ushering in a New Era of Business Software Creation Without Code
31.3.2026 13:00:00 CEST | Business Wire | Press Release
Softr today evolved into an AI-native platform, marking the end of the AI prototype era and the beginning of production-ready business software that non-technical teams can build, own, and maintain with AI — without writing a single line of code. With the introduction of its new AI Co-Builder, Softr enables teams to replace spreadsheets and manual workflows with secure, fully-functional business applications, including internal tools, customer portals, partner platforms, and operational systems, simply by describing what they need.
This milestone marks a major evolution for Softr, a leading player in the no-code software category over the past five years. Since launching in 2020, the company has grown to support more than 1 million builders and 7,000 organizations, including Netflix, Google, Stripe, UPS, and Clay.
Softr’s new platform was built to bridge the gap between AI-generated prototypes and software that can actually run business operations. Many AI app builders promise instant software from a single prompt, but stop at surface-level outputs, requiring users to manage code, fix errors, and rebuild workflows from scratch. Business software, on the other hand, runs on real data, connects to internal systems, and supports users with defined roles and permissions in real time — it has to work 100 percent of the time. When AI builders fall short or stop at the prototype, only a developer can fix it — resulting in months of work and hundreds of thousands of dollars to get software that should have been ready on day one. Softr closes that gap.
Softr’s new AI-native platform enables organizations to move from fragmented tools to fully operational software systems built in minutes — designed to run securely on live data, integrate with internal infrastructure, and provide structured access and governance from day one.
“For the first time, AI made the idea that ‘I can build something myself’ mainstream for millions of people — but most AI app-builders stop at the shiny demo stage,” said Mariam Hakobyan, Co-Founder and CEO of Softr. “We built Softr to solve the hard parts of software building. Every business app, from an internal HR portal to a client-facing tool, runs on real data, users, permissions, and security. It has to work every single time. Our goal has always been to give non-technical teams the ability to build the custom solutions they need without relying on developers. This evolution turns that vision into reality: software that helps people build and run the mission-critical software that powers their business operations.”
With the addition of Softr’s AI Co-Builder, users can describe the software they need in plain language, and the platform generates a fully integrated system — including the database, user interface, permissions, and business logic — connected and ready for real-world users immediately. Core foundations such as authentication, user roles, permissions, and hosting are built in from the start, eliminating the need for teams to configure or manage them separately.
Softr’s platform is built for business software that teams and customers can depend on every day. Each application is:
- Secure and fully functional from day one, with built-in authentication and permissions
- Powered by a visual, user-friendly database, giving users full control over their data
- Built on custom workflows and integrations, ensuring systems work seamlessly across tools
- Easy to maintain and evolve, without requiring code or repeated prompting
Teams use Softr to power critical workflows such as client portals, CRMs, company intranets, and operational systems across a wide range of industries. The company is now combining that profitable foundation with AI to accelerate its mission: to empower billions of business users to create production-ready software they can rely on from day one.
“The future of software isn’t written — it’s created,” Hakobyan added. “The next generation of software will be built by everyone — not because we simplified code, but because we simplified creation — and made building hard things easy.”
About Softr
Softr is the AI-native platform for building the software your business runs on—portals, internal tools, and operational systems—without code or developers. Describe what you need, and AI creates the database, app, and business logic—already connected, secure, and ready for real users. Over 1M+ organizations, from startups to enterprises like Netflix, Google, Stripe, UPS, and Clay, run their business operations on Softr-built apps. Visit softr.io to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260331754358/en/
Contacts
PR Contact
Kristin Lunt
softr@solcomms.co
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press Release
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press Release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press Release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press Release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom